Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2022 | 2020 | 2019 | 2018 | 2016 | 2015 | 2014 | 2013
Number of items: 14.

2022

Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan (Der Yu), Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140. S. 19 - 24. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz ORCID: 0000-0002-3411-6357, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle and Kater, Arnon P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 140 (8). S. 839 - 851. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

2020

Hillmen, Peter, Brown, Jennifer R., Eichhorst, Barbara F., Lamanna, Nicole ORCID: 0000-0003-3331-9491, O'Brien, Susan M., Qiu, Lugui, Salmi, Tommi, Hilger, James, Wu, Kenneth, Cohen, Aileen, Huang, Jane and Tam, Constantine S. (2020). ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol., 16 (10). S. 517 - 524. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Rhodes, Joanna, Sail, Kavita, Yazdy, Maryam, Hill, Brian, Shadman, Mazyar, Tuncer, Hande H., Winter, Allison, Kennard, Kaitlin, Allan, John, Ujjani, Chaitra, Brander, Danielle, Cho, Sang Kyu, Sharmokh, Simon, Jiang, Dingfeng, Nabhan, Chadi, Barr, Paul ORCID: 0000-0002-9733-401X, Brown, Jennifer, Fox, Christopher, Schuh, Anna, Eyre, Toby, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Wierda, William, Skarbnik, Alan, Roeker, Lindsey, Bannerji, Rajat, Evens, Andrew M., Pauff, James M., Schuster, Steven, Follows, George, Cheson, Bruce D., Eichhorst, Barbara and Mato, Anthony (2020). Factors impacting treatment selection in treatment-naive patients with CLL: a multicenter study. Leuk. Lymphoma, 61. S. 104 - 106. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Kim, Su Young, Wu, Jenny, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn and Kater, Arnon (2020). Time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): first presentation of 4-year data from the MURANO study. Leuk. Lymphoma, 61. S. 268 - 271. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

2019

Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M. and Stilgenbauer, Stephan (2019). Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J. Clin. Oncol., 37 (16). S. 1391 - 1405. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2018

Mato, Anthony R., Yazdy, Maryam Sarraf, Hill, Brian T., Shadman, Mazyar, Tuncer, Hande, Winter, Allison M., Kennard, Kaitlin, Allan, John N., Ujjani, Chaitra S., Brander, Danielle M., Nabhan, Chadi, Barr, Paul ORCID: 0000-0002-9733-401X, Brown, Jennifer R., Fox, Christopher P., Rhodes, Joanna, Schuh, Anna, Eyre, Toby A., Lamanna, Nicole, Jain, Nitin, Wierda, William G., Skarbnik, Alan P., Roeker, Lindsey E., Bannerji, Rajat, Evens, Andrew M., Lansigan, Frederick, Samp, Jennifer C., Nielsen, Jacqueline, Pauff, James M., Kipps, Thomas J., Schuster, Stephen J., Follows, George A., Cheson, Bruce and Eichhorst, Barbara (2018). Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole, Verdugo, Maria E., Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad and Kater, Arnon P. (2018). MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

2016

Sehn, Laurie H., Hallek, Michael, Jurczak, Wojciech, Brown, Jennifer R., Barr, Paul M., Catalano, John, Coutre, Steven E., Furman, Richard R., Lamanna, Nicole, Loic, Ysebaert, Zelenetz, Andrew D., Sharman, Jeffrey P., Devos, Sven, Adewoye, Adeboye Henry, Kim, Yeonhee, Flinn, Ian W. and Salles, Gilles A. (2016). A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

2015

Pagel, John M., Coutre, Steven E., Furman, Richard R., Sharman, Jeff P., Cheson, Bruce D., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Eradat, Herbert A., Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew, Li, Xiaoming, Jahn, Thomas M., O'Brien, Susan M. and Hallek, Michael J. (2015). Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia. Clin. Lymphoma Myeloma Leuk., 15. S. S201 - 2. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

2014

Coutre, Steven E., Furman, Richard R., Sharman, Jeff Porter, Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert Aaron, Ervin, Thomas J., Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew, Kim, Yeonhee, Jahn, Thomas Michael, O'Brien, Susan Mary and Hallek, Michael J. (2014). Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian ORCID: 0000-0001-6724-290X, Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D., Hallek, Michael and O'Brien, Susan M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 370 (11). S. 997 - 1008. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Ghia, Paolo, O'Brien, Susan Mary, Hillmen, Peter, Furman, Richard R., Coutre, Steven E., Sharman, Jeff Porter, Cheson, Bruce D., Pagel, John M., Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Eradat, Herbert Aaron, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Hallek, Michael J., Coiffier, Bertrand, Pettitt, Andrew, Ye, Wei, Jahn, Thomas Michael and Wagner, Lynne I. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2013

Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Hallek, Michael, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D. and O'Brien, Susan M. (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 122 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Tue May 7 09:24:56 2024 CEST.